

August 2, 2024

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

### **Announcement of Agreement of Joint Research on Multispecific Antibodies with Yamagata University, Osaka Metropolitan University, and Tokyo University of Agriculture and Technology**

Perseus Proteomics Inc. (“the Company”) is pleased to announce that it has signed an agreement of joint research on the development of generation and production technologies of new antibodies including multispecific antibodies with Yamagata University, Osaka Metropolitan University, and Tokyo University of Agriculture and Technology.

The purpose of this joint research is to develop technologies to efficiently generate and produce highly functional multispecific antibodies that can bind to multiple different targets through combining the diverse antibody library of the Company with the next-generation biopharmaceutical design technologies possessed by Prof. Koki Makabe at Yamagata University, Prof. Takeshi Nakanishi at Osaka Metropolitan University, and Prof. Ryutaro Asano at Tokyo University of Agriculture and Technology.

Multispecific antibodies are engineered to have properties to bind to two or more different antigens, enabling them to target different molecules or cells simultaneously. If the targets are cancer cells and immune cells, for example, the antibodies function to promote attack on cancer cells by immune cells. The Company will advance research and development for the creation of innovative antibody drugs through this agreement.

There is no impact on the business results of the fiscal year ending March 31, 2025.

END